Amiodarone and breast feeding

An infant was born at 33+2 weeks gestation by caesarean section after an in utero diagnosis of fetal ascesis and tachycardia. The mother had received treatment during pregnancy with flecainide, amiodarone, and propranolol. The amiodarone was prescribed initially at 200 mg three times a day and was reduced to twice a day after 11 days. The mother was keen to breast feed the baby. In previous reports of amiodarone and breast feeding, amiodarone treatment was for a maternal indication and hence continued post partum.1,2 In this case, the amiodarone treatment stopped at delivery. However, because of the long terminal half life of amiodarone (about 50 days),1 it could take several months for the level to fall. As one of the adverse effects of amiodarone is thyroid toxicity, the baby's thyroid function was assessed and found to be normal. A decision was made to allow the mother to breast feed, and the baby was closely monitored.

Breast milk was sent for analysis to determine the amiodarone level on days 5, 11, 18, and 25. It had increased on day 11 (2.1 mg/l) compared with day 5 (0.6 mg/l). This may be due to changes in composition of the milk. We do not know at what time of day the milk was expressed or whether the sample was taken at the beginning or the end of the feed. The fat content of the milk was likely to be greater after 11 days than after 5 days, which may affect the distribution of amiodarone. McKenna et al.3 described changes in amiodarone concentration in breast milk throughout the day. By 25 days, amiodarone was undetectable. Throughout this period the baby remained well and thyroid function was normal.

Although we would not recommend that breast feeding is necessarily safe for all babies exposed to amiodarone, this case illustrates that, in some circumstances, with close monitoring, breast feeding can be initiated.

References

3 Sanofi-Synthelabo. Summary of product characteristics. Cordarone X. Sanofi-Synthelabo, UK.

Reducing antibiotic use on the neonatal unit by improving communication of blood culture results: a completed audit cycle

It is common clinical practice to discontinue antibiotic treatment of asymptomatic babies if the blood cultures are negative at 48 hours.1,2 However, if blood culture results are only available during the normal working day, then antibiotic treatment of some babies may continue into the next working day. In our neonatal unit, blood culture results were routinely received from the microbiology laboratory via fax as a list every morning. Extra positive results would be telephoned through, if they became available, during the normal working day. Results could also be checked by the clinical staff telephoning the laboratory during “office hours”. This gave the potential for inadvertent prolongation of antibiotic courses for up to a day. In a previous study, McDonald et al.3 found this to be a common occurrence. It is of concern because unnecessary antibiotic use may contribute to antibiotic pressure within the neonatal unit and may encourage the selection of drug resistant organisms.

We performed two audits into this problem within our neonatal unit. Our audit standard on each occasion was that antibiotics should be stopped at 48 hours, if blood cultures were negative, unless a decision to continue was clearly documented in the case notes. Babies with negative blood cultures were identified from the microbiology database. Each episode was classified into one of four groups: (a) antibiotics not started; (b) antibiotics stopped within 48 hours; (c) antibiotics given for more than 48 hours deliberately; (d) antibiotics given for more than 48 hours unintentionally.

The results are summarised in table 1.

The first audit was conducted on 451 babies with negative blood cultures between January 1997 and December 1998. We were able to collect complete data from case notes and drug charts for 376 (83.4%) of these blood cultures. We found that the audit standard was not met in 144/376 (38.3%). The median (range) duration of antibiotic treatment for each baby was 60 (16.9–332) hours.

The blood culture analyst in use in our laboratory (BactAlert Microbial Detection System; Organon Teknika Corporation, Durham, North Carolina, USA) tests for bacterial growth every 10 minutes and communicates the blood culture status (positive or negative) to a computer. After our initial audit, we established a computer link between the blood culture analyser and the neonatal unit. This allows the clinical staff to check the status of any blood culture in the analyser in real time, 24 hours a day.

The second audit was performed on babies with negative blood cultures between May 2000 and August 2000. Two hundred negative blood cultures were identified. Complete data were available for 179/200 (89.5%). The audit standard was not met in only 20/179 (11.2%); p<0.0001 compared with the first audit. The median (range) duration of treatment was reduced to 48 (1–182) hours (p<0.0001). There was an overall reduction of two doses of antibiotic per baby (from a mean of 8.8 to 6.8 doses per baby).

We estimated that we gave 21 684 doses of antibiotics on the neonatal unit between January 1997 and December 1998. If the computer system had been in operation during this period, we estimate that we could have reduced this by 16.2% to 18 169. We think that this magnitude of reduction in antibiotic pressure on the neonatal unit is worth achieving.

M A Jardine, Y Kumar, S Kausalya, S Harigopal, J Wong, A Shivaram, T J Neel, C W Yoxall

Correspondence to: Dr Yoxall, Liverpool Women’s Hospital, Crown Street, Liverpool L8 7SS, UK; Bill.Yoxall@wkrhs.nwest.nhs.uk

Table 1 Reduction in unintentional antibiotic use over 48 hours after introduction of real time availability of blood culture status by a computer link between the blood culture machine and our neonatal unit

<table>
<thead>
<tr>
<th>Results</th>
<th>No antibiotics started</th>
<th>Antibiotics stopped after &gt;48 h</th>
<th>Antibiotics continued for &gt;48 h deliberately</th>
<th>Antibiotics continued for &gt;48 h unintentionally</th>
</tr>
</thead>
<tbody>
<tr>
<td>First audit</td>
<td>25 (6.6%)</td>
<td>132 (35.1%)</td>
<td>75 (19.9%)</td>
<td>144 (38.3%)</td>
</tr>
<tr>
<td>Second audit</td>
<td>15 (8.4%)</td>
<td>117 (65.4%)</td>
<td>27 (15.1%)</td>
<td>20 (11.2%)</td>
</tr>
</tbody>
</table>
References


Preventing hypothermia at birth in preterm babies: at a cost of overheating some?

In the Epicure study, the odds ratio of death before discharge for babies whose temperature on admission to the neonatal unit was > 35°C was 0.58 (95% confidence interval (CI) 0.39 to 0.85) compared with those with lower temperatures. In 2001, we therefore introduced a policy of wrapping neonates < 30 weeks gestation in polythene bags at birth without first drying them. Temperatures on admission to the neonatal unit after the introduction of this policy were compared with those of historical controls of < 30 weeks gestation admitted unwrapped between 1996 and 2000. The admission temperatures were analysed by stepwise multiple regression against being “bagged” or not, time to admission to the unit, birth weight, gestation, mode of delivery, month of delivery, and maternal temperature.

• being bagged +0.35°C (0.09 to 0.62) (co-efficient, 95% CI);
• time to admission −0.02°C (−0.01 to −0.03) per minute;
• birth weight +0.07°C (0.02 to 0.1) per 100 g;
• gestation +0.0007°C (0.0002 to 0.001) °C per week.

Thus “bagging” increased admission temperatures by 0.35°C, which is rather less than the rise of 1.9°C in babies < 28 weeks gestation reported in a previous study.1

Table 1 shows that, in the comparable groups, this rise of 0.35°C resulted in a significant reduction in incidence of hypothermia (<35.5°C) in “bagged” babies. However, significantly more of them (12%) were hyperthermic (>37°C), a phenomenon previously reported but not discussed.3 The risks of hypothermia are less well defined than those of hyperthermia, but it may increase the risk of anticoagulant-related arterial or saphenous vein problems.4

We therefore use a method whereby the vein, using the Selddinger technique, is ultimately cannulated with a 20 GA catheter through which the silastic line can be inserted.

(1) The procedure should be carried out under optimal conditions using an aseptic technique. If the infant is already ventilated, we advocate the use of a muscle relaxant as well as adequate sedation. This is especially advisable for insertion of femoral venous lines.

(2) The vein is initially cannulated with a 24 GA (external diameter 0.7 mm) cannula. The sites most often used are the great saphenous vein at the ankle or knee joint, the femoral vein, the basilic or cephalic veins in the antecubital fossa, or, occasionally, the superficial temporal vein. A transilluminator or “cold light” inserted into the finger of a sterile glove can be of use in locating deep veins as well as protecting the sterile field.

(3) A guidewire is then inserted through the cannula into the vein. We use a “duoflex spring wire guide”: diameter 0.45 mm, length 25 cm (duoflex spring wire guide manufactured by Arrow; product no AW-04018; cost £159.90). It is packaged with a metal 19 GA butterfly needle for use in insertion of the line.

This technique has some drawbacks.

(1) The 19 GA needle is difficult to put directly into neonatal veins because of its large size.

(2) It can be difficult to appreciate “flash back” of blood into the metal needle.

(3) It is not possible to “flush” the needle to ensure correct positioning of the line as well as patency of the vessel.

(4) It is not feasible to place femoral venous lines using this method.

Swaddling and heat loss

The letter of Hawkes et al1 raises the important issues of swaddling and temperature on admission to the neonatal unit. Besch et al2 carried out a limited comparison of different swaddling materials and found a transparent plastic bag together with radiant heat to be effective in preventing heat loss in infants over 2 kg. Following a report in the literature,3 we have begun wrapping all preterm infants < 1000 g in a thin plastic wrap. The wrap is preheated on a radiant warmer and the infant is immediately placed (undried) on the plastic sheet, which is folded over to (but loosely) enclose the torso and extremities from the neck down. The infant is left in the wrap until transported to the neonatal unit and the temperature has stabilised in a humidified environment. The median temperature of the 19 < 1000 g infants admitted since wrapping was commenced was 36.7°C on arrival to the nursery compared with 35.5°C for the previous 86 unwrapped infants (p = 0.002; using Mann-Whitney U test). There were no significant differences in birth weight, gestational age or Apgar scores between the groups.

Although our experience is in smaller preterm infants (who are more prone to hypothermia), our results are in keeping with previous studies. The infant is left in the wrap until transported to the neonatal unit and the temperature has stabilised in a humidified environment. The median temperature of the 19 < 1000 g infants admitted since wrapping was commenced was 36.7°C on arrival to the nursery compared with 35.5°C for the previous 86 unwrapped infants (p = 0.002; using Mann-Whitney U test). There were no significant differences in birth weight, gestational age or Apgar scores between the groups.

Although our experience is in smaller preterm infants (who are more prone to hypothermia), our results are in keeping with those of Vohra et al, who studied infants < 32 weeks.3 We now plan to wrap all preterm infants < 1500 g.

The plastic wrap is likely to be more effective than towels because of reduction in evaporative heat loss and because it allows observation of the infant. However, the plastic wrap is unlikely to significantly reduce radiant heat loss, so an additional heat source is essential for preterm infants. Some form of head swaddling is also important and needs further study. Aluminum foil may reduce evaporative, convective, and radiant heat loss but does not allow observation or radiant warming.

It appears there are many aspects of swaddling that require further investigation.

T Newton, M Watkinson
Neonatal Unit, Birmingham Heartlands Hospital, Birmingham, UK;
michael.watkinson@heartsol.wmids.nhs.uk

References


Technique for insertion of percutaneous central venous catheters in the newborn period

The use of percutaneous central venous catheters is of proven value for the provision of parenteral nutrition and intravenous drug treatment in neonates. They have become an integral part of the management of very low birthweight infants in most intensive care units.

At the Royal Children’s Hospital in Melbourne we used a silastic catheter, which has an external diameter of 0.6 mm and comes in a variety of different lengths (Epicutaneo-Avance catheter manufactured by Vygon; lengths 15, 30, and 50 cm; ref nos 2184.015, 2184.00, and 2184.005; cost AU$59.10). It is packaged with a metal 19 GA butterfly needle for use in insertion of the line.

Table 1 Incidence of hypothermia and hyperthermia in control babies and babies wrapped in polythene bags (study group)

<table>
<thead>
<tr>
<th>Control group</th>
<th>Study group</th>
<th>Difference (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>230</td>
<td>48</td>
</tr>
<tr>
<td>Gestation (weeks)</td>
<td>28 (23–29)</td>
<td>17 (10–29)</td>
</tr>
<tr>
<td>Weight (g)</td>
<td>1020 (400–1900)</td>
<td>1027 (500–1700)</td>
</tr>
<tr>
<td>Number &lt;35.5°C</td>
<td>96 (42)</td>
<td>12 (5.4)</td>
</tr>
<tr>
<td>Number &gt;37°C</td>
<td>1 (0.4)</td>
<td>6 (2.5)</td>
</tr>
</tbody>
</table>

Values are either median (range) or number (%). Cl, Confidence interval.

www.archdischild.com
Umbilical granulomas: a randomised controlled trial

The Archimedes section has previously contained a brief section on the treatment of umbilical granulomas. We have now conducted a randomised controlled trial of the management of umbilical granulomas. The trial compared silver nitrate cauterisation with the use of alcoholic wipes at each nappy change (conservative management). The aim for this work was a series of three burns to the anterior abdominal wall after silver nitrate cauterisation, seen in a single London hospital over a two year period.

The trial aimed to show equivalence between the two treatment modalities. On the basis of equal efficacy, we intended to change practice to conservative management. More than 40 infants were referred, but a large number of parents chose conservative management rather than randomisation. Difficulty in recruitment meant there were inadequate numbers to show statistical significance within the limited time span available.

The salient results were that two of three granulomas resolved over a three week period without cauterisation. Those infants whose granulomas did not resolve went on to treatment with cauterisation following a protocol that involved drying the area both before and after silver nitrate application, surrounding the umbilicus with white soft paraffin, and leaving the area exposed for 10 minutes after application. This resulted in resolution in all remaining cases without harm due to delay in treatment.

On the basis of this work, we suggest a change in current practice to initial conservative management followed by cauterisation only when conservative treatment fails.

J Daniels
Hometor Hospital, London, UK
F Croag
Great Ormond Street Hospital, London, UK
R Wojed
Northwick Park Hospital, London, UK
M Meates
North Middlesex Hospital, London, UK

Correspondence to: Dr Daniels, Hometor Hospital, London, UK; Justin.Daniels@virgin.net

References


Progressive ventricular dilatation (PVD) over the past 22 years

We read with interest the article of Murphy et al., and it prompted us to review our own experience with progressive ventricular dilatation (PVD) over the past 22 years at the Maine Medical Center (MMC). Since 1980, we have used a simple approach to management of PVD. As noted in previous publications, we have considered the need for intervention to be rapid head growth defined as an increase in occipitofrontal circumference of 2 cm a week or more rather than relying on imaging. As this degree of head growth suggests increased intracranial pressure, we have intervened by directly draining ventricular fluid through a 21 gauge angiocath placed in the right coronal suture into the right lateral ventricle. This catheter is connected to a ventriculostomy drainage system, and drainage is continued for seven days if possible. The catheter is then removed and the decrease in head circumference and ventricular size recorded. The infant is watched for return of rapid head growth, and an angiocath is reinserted as needed. This procedure is repeated until the infant reaches about 2 kg in weight, and if rapid head growth continues, a permanent ventriculoperitoneal shunt is placed. We do not use pharmacological treatment or repeat lumbar puncture to treat PVD.

As pointed out by Murphy et al., PVD sufficient to require intervention occurs almost exclusively in infants with grade 3 or 4 intraventricular haemorrhage (IVH). As expected, the very low birthweight infants with grade IVH have a high mortality rate. As shows a comparison between the outcomes for grade 3–4 IVH at MMC during the 1980s and over the past five years (1997–2001 inclusive), and the data of Murphy et al. grouped in the same way. As noted, there is little difference over time or between studies. Overall mortality for grade 3–4 IVH was 33% (26/79) for Murphy et al., 33% (31/94) for MMC in the 1980s, and 31% (27/88) for MMC in 1997–2001. Until grade 3–4 IVH can be eliminated, posthaemorrhagic hydrocephalus will continue to occur with high morbidity and mortality.

Department of Pediatrics, Maine Medical Center, Portland, Maine, USA; weissl@mmc.org

References


Table 1 Comparison between the outcomes for grade 3–4 intraventricular haemorrhage (IVH) in the three studies

<table>
<thead>
<tr>
<th></th>
<th>Murphy et al1</th>
<th>MMC 1980s2</th>
<th>MMC 1997–2001</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 3–4 IVH (% of all &lt;1500 g)</td>
<td>79(7%)</td>
<td>94(6%)</td>
<td>29(6%)</td>
</tr>
<tr>
<td>Death &lt;14 days</td>
<td>18/79(23%)</td>
<td>29/94(30%)**</td>
<td>8/29(28%)**</td>
</tr>
<tr>
<td>PVD requiring treatment</td>
<td>34/61(56%)</td>
<td>24/65(37%)</td>
<td>11/21(52%)</td>
</tr>
<tr>
<td>VP shunt/late death (% of PVD treatment)</td>
<td>18/8 (26/34=76%)</td>
<td>12/3(15/24=63%)</td>
<td>6/1(7/11=63%)</td>
</tr>
</tbody>
</table>

*Rate for all infants <35 weeks.
**Rate for all deaths <30 days.
MMC, Maine Medical Center; PVD, progressive ventricular dilatation; VP, ventriculoperitoneal.
Do we need to assess the thyroid function in the infants of mothers with Hashimoto’s thyroiditis?

We read with interest the recent comprehensive review of neonatal thyroid disorders, which gave evidence-based answers to many important questions. The author recommended that all babies born to mothers with Hashimoto’s thyroiditis should be reviewed at 10 days to 2 weeks and a thyroid function test taken because infants may develop transient hypothyroidism or, very rarely, hyperthyroidism.1

As paediatricians, in a hospital with a paediatric endocrine caseload similar to some tertiary centres and a subregional neonatal intensive care unit with local deliveries of 6000 per annum, we think that the potential benefits of this practice are difficult to justify. We do understand that such practice will help in identifying babies who may develop transient congenital hypothyroidism caused by maternal thyrotropin receptor blocking antibodies. However, the incidence of this form of hypothyroidism has been estimated to be 1 in 180 000 normal infants (~2 % of congenital hypothyroidism) and the majority of them will have raised thyroid stimulation hormone levels that can be detected by the current neonatal screening.2 Based on a simple calculation, in a unit of our size only one baby will be detected every 30 years. We feel that there would be major disadvantages if we are to adopt the author’s recommendation. Firstly, an extra hospital visit for babies and parents; secondly the need to bleed many healthy infants; and finally the potential for confusion and unnecessary anxiety. Until objective evidence emerges about the significance of subclinical thyroid dysfunction in early life we feel that the current screening programme should not be extended.

A M Habeb
Paediatric Department, Hull Royal Infirmary; abdul.habeb@hey.nhs.uk

M Zubier, P Pairaudeau, V Mathew
Paediatric Department, Hull Royal Infirmary

References

CORRECTIONS

In the CD Review (Arch Dis Child Fetal Neonatal Ed 2003;88:F164) reviewed by C Wren, please note that the affiliation of the authors is published incorrectly. This should have read Royal Prince Alfred Hospital, Sydney. Also, the web address in the final paragraph is incomplete. The correct address is: http://www.cs.nsw.gov.au/rpa/neonatal/default.htm. The errors are much regretted.

The authors would like to acknowledge and apologise for an error in our article Socioeconomic status and preterm birth: New Zealand trends, 1980 to 1999. ED Craig, JMD Thompson, EA Mitchell (Arch Dis Child Fetal Neonatal Ed 2002;86:F142-6).

Paragraph four in the Results section should read “Figure 2 summarises changes in preterm birth rates by Deprivation Index decile between 1980 and 1999. During this period rates rose from 5.2% to 5.9% among those living in the most deprived areas (a 13.5% increase), from 4.0 to 5.5% amongst those living in average areas (a 37.3% increase) and from 3.1% to 5.4% amongst those living in the least deprived areas (a 74.2% increase). Thus while in 1980 a marked social gradient in preterm birth existed, by 1999 this has diminished markedly.” Table 2 and table 3 are amended. These errors do not significantly change the reported trends in preterm birth or the interpretation of the findings previously published.

Table 2 Multivariate odds ratios for preterm birth by gestational age category and Deprivation Index decile; New Zealand singleton live births 1980, 1990, and 1999

<table>
<thead>
<tr>
<th>Year</th>
<th>NZDep Index Decile</th>
<th>Gestational age category</th>
<th>All preterm (n=51 711) OR*</th>
<th>20–27 weeks (n=26 979) OR**</th>
<th>28–33 weeks (n=12 703) OR*</th>
<th>34–36 weeks (n=36 311) OR*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1980</td>
<td>1</td>
<td>1.00</td>
<td>1.00</td>
<td>1.00</td>
<td>1.00</td>
<td></td>
</tr>
<tr>
<td>1980</td>
<td>5</td>
<td>1.15</td>
<td>1.08</td>
<td>1.16</td>
<td>1.15</td>
<td></td>
</tr>
<tr>
<td>1980</td>
<td>10</td>
<td>1.36</td>
<td>1.18</td>
<td>1.39</td>
<td>1.36</td>
<td></td>
</tr>
<tr>
<td>1990</td>
<td>1</td>
<td>1.30</td>
<td>1.31</td>
<td>1.21</td>
<td>1.33</td>
<td></td>
</tr>
<tr>
<td>1990</td>
<td>5</td>
<td>1.44</td>
<td>1.45</td>
<td>1.34</td>
<td>1.47</td>
<td></td>
</tr>
<tr>
<td>1990</td>
<td>10</td>
<td>1.63</td>
<td>1.66</td>
<td>1.52</td>
<td>1.67</td>
<td></td>
</tr>
<tr>
<td>1999</td>
<td>1</td>
<td>1.64</td>
<td>1.67</td>
<td>1.44</td>
<td>1.72</td>
<td></td>
</tr>
<tr>
<td>1999</td>
<td>5</td>
<td>1.76</td>
<td>1.91</td>
<td>1.53</td>
<td>1.84</td>
<td></td>
</tr>
<tr>
<td>1999</td>
<td>10</td>
<td>1.93</td>
<td>2.25</td>
<td>1.64</td>
<td>2.02</td>
<td></td>
</tr>
</tbody>
</table>

Multivariate analysis adjusted for gender, maternal age, parity, birth year, decile and birth year*decile, year*age, year*parity, decile*age, decile*parity.

*Odds ratios (OR) with reference category deprivation index decile 1, 1980.

Table 3 The “social gradient in preterm birth”; risk of preterm birth amongst decile 10 women compared to decile 1 women (same year), New Zealand singleton live births 1980, 1990, and 1999

<table>
<thead>
<tr>
<th>Year</th>
<th>All preterm (n=51 711) OR*</th>
<th>20–27 weeks (n=26 979) OR**</th>
<th>28–33 weeks (n=12 703) OR*</th>
<th>34–36 weeks (n=36 311) OR*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1980</td>
<td>1.36</td>
<td>1.18</td>
<td>1.39</td>
<td>1.36</td>
</tr>
<tr>
<td>1990</td>
<td>1.26</td>
<td>1.27</td>
<td>1.25</td>
<td>1.26</td>
</tr>
<tr>
<td>1999</td>
<td>1.17</td>
<td>1.35</td>
<td>1.14</td>
<td>1.17</td>
</tr>
</tbody>
</table>

Multivariate analysis adjusted for gender, maternal age, parity, birth year, decile and birth year*decile, year*age, year*parity, decile*age, decile*parity.

*Odds ratios (OR) for preterm birth amongst decile 10 women compared to those in decile 1 for each particular year reflects the social gradient for that year.

*Odds ratios for the 20–27 week category did not reach statistical significance.
Umbilical granulomas: a randomised controlled trial

J Daniels, F Craig, R Wajed and M Meates

Arch Dis Child Fetal Neonatal Ed 2003 88: F257
doi: 10.1136/fn.88.3.F257

Updated information and services can be found at:
http://fn.bmj.com/content/88/3/F257.1

These include:

Supplementary Material
Supplementary material can be found at:
http://fn.bmj.com/content/suppl/2004/05/27/88.3.F257.DC1

References
This article cites 1 articles, 1 of which you can access for free at:
http://fn.bmj.com/content/88/3/F257.1#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Errata
An erratum has been published regarding this article. Please see next page or:
/content/88/5/F446.3.full.pdf
/content/89/4/F376.3.full.pdf

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/
Late anaemia in Rh haemolytic disease

As it is clearly stated in the review by Gottstein and Cooke,1 we consider it unethical to withhold or delay high dose intravenous immunoglobulin (IVIG) treatment in infants with haemolytic disease of the newborn. Since the study we did in 1995,2 we have treated 129 patients with Coombs’s positive haemolytic disease of the newborn, with the same method and had to resort to exchange transfusions only in three cases. On the other hand, late anaemia is a frequent problem in these cases, necessitating multiple blood transfusions, with well known complications.

The authors suggest that multiple doses of IVIG may reduce late anaemia. However, our observation in a limited number of cases is that, even multiple doses of IVIG are ineffective in preventing late anaemia. In an earlier unpublished study, we had shown that the erythropoietin levels were low in these infants. Therefore, we had conducted a double blind, randomised pilot study to investigate the effects of recombinant erythropoietin (rHEPO) in these patients.3 In this study, rHEPO was administered at a dose of 200 units/kg, subcutaneously, three times a week, starting at the 14th day of life and lasting for six weeks. This protocol reduced the number of erythrocyte transfusions significantly. With the impetus of this pilot study, we have used the same protocol for the subsequent 103 patients and the mean number of transfusions in this group was 1.5, with the majority of patients (50%) not needing any transfusions at all. There were no complications, including changes in neutrophil or platelet counts, and haemorrhagic or infectious complications. The administration of rHEPO to patients with haemolytic disease of the newborn, who had received IVIG early in life, not only decreases the infants’ exposure to multiple blood donors, but also diminishes the need for hospitalisation and hence the cost that is involved. Therefore, rHEPO treatment is a suitable alternative to erythrocyte transfusions in these infants.

Systematic review of intravenous immunoglobulin in haemolytic disease of the newborn

We read with interest the recent review of Gottstein and Cooke.1 Their systematic review of trials reporting treatment of infants with proven Rh and/or ABO haemolytic disease of the newborn (HDN) treated with high dose intravenous immunoglobulin (HDIVIG) and phototherapy, with phototherapy alone demonstrated that significantly fewer infants required exchange transfusion in the HDIVIG group. The authors point out that anti-D is the commonest red cell antibody responsible for HDN. We have recently treated two children both of whom developed evidence of immune haemolysis due to anti-D antibodies acquired from IVIG.

The first patient, a 4 month old infant with Kawasaki’s disease, was treated with intravenous immunoglobulin (2g/kg) with immediate control of fever and irritability. Ten days later her disease became clinically active again and she was therefore given a second dose of IVIG (2g/kg from a different batch), which is a recognised therapeutic option.4 Her clinical condition again improved rapidly. A blood count two days after the second dose of IVIG showed that her haemoglobin had fallen suddenly by 2g/dl to 6.4g/dl, the blood film showed spherocytes and the direct antiglobulin test was positive, evidence of immune haemolysis. Samples that were collected prior to the second dose of IVIG confirmed her blood group to be AB Rh D positive with a negative direct antiglobulin test. Anti-D antibodies were not detected in the patient’s serum; these were not present in her mother whose antibody screen was negative and whose blood group was A Rhessus D positive. The manufacturer of the IVIG investigated the batches used and reported that the IVIG used for the second dose contained anti-D. The second patient, a 1 year old boy with systemic juvenile idiopathic arthritis received a fifth dose of IVIG from the same batch. He was screened for evidence of haemolysis and his antiglobulin test was positive 14 days after treatment. He remained asymptomatic with no fall in haemoglobin.

IVIG is an inactivated blood product not a drug; each batch is made from a pool of plasma collected from several thousand donors. Passive transfer of potentially significant red cell antibodies is a recognised hazard, reported in the company literature but only as a serological phenomenon, not as a clinical warning.

The first case is a reminder that such complications may have serious clinical consequences. We would agree with the comment of Gottstein and Cooke that the use of IVIG is not without potential risks, including haemolysis. IVIG is not universally effective in autoimmune haemolysis in older children and adults where steroids are the first choice.

Indications for the use of IVIG must be clear and evidence based, and as with all pooled blood products, including albumin solutions, the individual batch numbers must be recorded in the case notes, so that adverse events can be appropriately and fully investigated.

A G Cleary, B Brown, J Minards, J Sills
Royal Liverpool Children’s Hospital, Liverpool, UK;
gavin.cleary@rlch.tr.nwest.nhs.uk

High dose intravenous immunoglobulin in haemolytic disease of neonates

It was encouraging to read article of Gottstein et al,5 on the use of high dose intravenous immunoglobulin (HDIVIG) in cases of haemolytic disease of newborns (HDN) with their conclusion showing the effectiveness of HDIVIG. I have the following observations to make with respect to implications on practice and future research.

Firstly, all the references mentioned were between three and ten years old.*** These trials did not take into consideration the irradiance of the phototherapy used, although they did observe the number of exchange transfusions performed. Presently, a combination of blue and white fluorescent light double surface phototherapy, with effective higher irradiances of 20–40 W/cm2/mm, can practically eliminate the need for exchange transfusion, even in severe cases of HDN. Irradiance of phototherapy can be increased further by decreasing the distance between the phototherapy unit and the patient, especially with an undersurface phototherapy unit, keeping thermal and nursing issues under consideration.

Secondly, the authors did not address enterohemorrhagic recirculation of bilirubin from the gut. Inexpensive measures can decrease the back entry of bilirubin from gut, like early enteral feeds, oral administration of agar agar, isabagol husk and so forth, and further reduce serum bilirubin levels. Further randomised controlled trials are required before administration of HDIVIG becomes routine in HDN. These trials should compare use of current effective phototherapy combinations with the
highest possible irradiance, agents that de-crease enterohepatic recirculation of bilirubin with or without HIDIVIG, and the need for exchange transfusion in HDN. They should also address cost effectiveness and safety, considering the cost of HIDIVIG in the developing world.

G Gupta
Armed forces Medical College, Pune, India; guptas@rediffmail.com

References

Authors’ reply
We are grateful to our colleagues for their interest and responses to our paper.1 In response to Dr Ovaly’s comments we agree that late anaemia can be a problem in babies who receive intravenous immunoglobulin (IVIG), as is also demonstrated in our systematic review. Even when infants have received exchange transfusions (XTs) top up red cell transfusions may be required. In a recent local audit of XTs, 35% of babies received top up red cell transfusions after one or more exchange transfusions. During a five year period from 1998–2002, 27 babies with Rhesus, Kell, or ABO incompatibility had 28 XTs. Gestation ranged from 28 to 40 completed weeks. Of 26 infants for whom follow up data was available, nine (35%) had received top up red cell transfusions.

We read with interest Dr Ovaly and colleagues paper describing a double blind randomised controlled trial of subcutaneous recombinant human erythropoietin (rHepoE) and its use in this situation.1 We await with interest the outcome of a Cochrane meta-analysis of this therapy in newborn infants (currently at the protocol stage).

We reviewed our computer database for a three month period from December 1999 to December 2002 to postulate what impact IVIG might have on our population of babies with haemolytic disease of the newborn. Two hundred and five babies had a positive direct Coombs test (DCT) result. Of these, 12 infants, 2 received XTs. There is a degree of under ascertainment with this database as there were four additional babies who required an XT during this time period. However, we make the assumption that the proportions of those missing requiring XTs is similar to the proportions of DCT positive babies who were missed from the database. Eighty five babies had moderate or strongly positive DCT. Of these 11 received an XT, giving an XT rate in this group of 13%. After IVIG the relative risk of requiring an XT is 0.28,1 thus with IVIG the XT rate would be reduced to 3.6%, decreasing the number of XTs to three and therefore preventing eight. If IVIG were administered to all babies with moderate or strongly positive DCT, in our population the number needed to treat would be 10.6 to prevent one XT. The degree of positivity of the DCT is an objective validated assessment of the strength of antigen/antibody reaction, determined by the degree of agglutination in the laboratory.1 During the three year period of this database there was only one infant who had only a weakly positive DCT and required an XT. We were interested to read Dr Cleary and colleagues case reports. We recognise that IVIG is not specific for a particular type of haemolysis and that it is a pooled blood product. We therefore agree that all the usual procedures regarding documentation of batch number and so on are followed as for any other blood product. IVIG has been used previously even in preterm and low birthweight infants1 and is currently being used in the INIS Trial.1 As with any drug, the blood product we will need to remain vigilant for the occurrence of any adverse events.

R Gottstein, RWI Cooke
Neonatal Unit, Liverpool Women’s Hospital, Liverpool L8 7SS, UK; rgottstein@nflworld.com

References

Role of serum peak levels of vancomycin in neonatal intensive care units

We would like to comment on the article by Tan et al.1 The purpose of measuring serum levels of a drug is either to monitor the toxicity of the drug or the therapeutic concentration for a particular condition. Emergence of infections with β-lactam-resistant Staphylococcus epidermidis, Staphylococcus aureus, and Enterococcus sp, has led to the frequent use of vancomycin in neonates. Vancomycin has historically had a reputation for toxicity. Many of its original adverse reactions, including ototoxicity and nephrotoxicity, were probably due to improper formulation.1 Now, that a more purified form is available, these adverse reactions are uncommon. However, concomitant administration with aminoglycosides or other nephrotoxins may increase the risk of toxicity.1 Effective drug therapy is measured by response, not by achievement of a particular circulating drug concentration. Because the association between vancomycin peak concentrations and toxicity is poor, some have recommended measuring trough concentration only1 as this study is clearly documenting, but others have suggested not measuring any concentrations in the majority of children with normal renal function.1 However, in critically ill premature neonates with poor glomerular filtration rate, prematurity, and compromised cardiovascular function, it remains prudent to measure both peak and trough concentrations in those with poor or changing renal function. Caution must be exercised when other nephrotoxic or ototoxic drugs such as aminoglycosides are administered concurrently.1 In this study, the authors did not mention the concomitant use of aminoglycoside.

S Jain
Southen Illinois University School of Medicine, Springfield Illinois, USA; jeinsunil@hotmail.com

References
of any clinical finding; again, the catheter tip was sterile. Methaemoglobin concentration was still abnormal (6.2%). Liposomal amphotericin B treatment was prolonged for a further six days and then discontinued. At this time, methaemoglobin levels were near normal (3%), and blood cultures were negative. The gastrointestinal symptoms resolved with age and full gastrointestinal function was achieved.

Recovery of Saccharomyces two weeks after administration had been stopped suggests persistence in the gut. It is tempting to think that the methaemoglobinemia was caused by the continued presence of the yeasts, perhaps through excessive host production of nitric oxide. Several studies have shown that nitric oxide plays a pivotal role in the interaction between yeasts and the phagocytic system, and it is well known that this radical readily oxidises haemoglobin. It is also reasonable to link late bloodstream invasion by Saccharomyces to previous enteric mucosal damage caused by a Candida infection, which was itself probably gut related. The recovery of S cerevisiae in place of S boulardii has been reported by others, and can be explained by the similarities between the two. It is ironic that the intervention used to prevent sepsis from enteric overgrowth not only did not succeed but was itself a cause of the problem that it was intended to prevent.

M S Lungarotti, D Mezzetti, M Radiconi Policlínica Manteluce, Via Brunamonti, Perugia, PG 06100, Italy; dm2@unipg.it

References

Methaemoglobinemia with concurrent blood isolation of Saccharomyces and Candida

Saccharomyces boulardii is closely related to Saccharomyces cerevisiae and is used as a biotherapeutic agent, although some reports suggest pathogenicity. We present a case of neonatal fungaemia with concurrent methaemoglobinemia, occurring after a brief period of treatment with S boulardii. A male infant was born at 30 weeks of gestational age by caesarean section because of intrauterine growth restriction and maternal hypertension. The baby was well apart from persistent gastrointestinal symptoms that hampered feeding and forced parenteral support. During the third week of life, administration of S boulardii (Codex DNB; half a capsule a day, equivalent to 2.5 x 10^10 organisms) was started in an attempt to prevent bacterial overgrowth. After four days of treatment, the baby developed symptoms suggesting sepsis and an unexplained methaemoglobinemia (methaemoglobin concentration = 16%). Codex was stopped and empirical antibiotic coverage, including liposomal amphotericin B, was started. Blood cultures showed growth of Candida albicans, but the central venous catheter tip was negative. Methaemoglobin levels halved in two days (7%), but remained constant during the following two weeks of antifungal treatment. Blood cultures at that point showed growth of S cerevisiae, which is susceptible to amphotericin B, in the absence of any clinical finding; again, the catheter tip was sterile. Methaemoglobin concentration was still abnormal (6.2%). Liposomal amphotericin B treatment was prolonged for a further six days and then discontinued. At this time, methaemoglobin levels were near normal (3%), and blood cultures were negative. The gastrointestinal symptoms resolved with age and full gastrointestinal function was achieved.

M S Lungarotti, D Mezzetti, M Radiconi

Policlínica Manteluce, Via Brunamonti, Perugia, PG 06100, Italy; dm2@unipg.it

References

Methaemoglobinemia with concurrent blood isolation of Saccharomyces and Candida

Saccharomyces boulardii is closely related to Saccharomyces cerevisiae and is used as a biotherapeutic agent, although some reports suggest pathogenicity. We present a case of neonatal fungaemia with concurrent methaemoglobinemia, occurring after a brief period of treatment with S boulardii. A male infant was born at 30 weeks of gestational age by caesarean section because of intrauterine growth restriction and maternal hypertension. The baby was well apart from persistent gastrointestinal symptoms that hampered feeding and forced parenteral support. During the third week of life, administration of S boulardii (Codex DNB; half a capsule a day, equivalent to 2.5 x 10^10 organisms) was started in an attempt to prevent bacterial overgrowth. After four days of treatment, the baby developed symptoms suggesting sepsis and an unexplained methaemoglobinemia (methaemoglobin concentration = 16%). Codex was stopped and empirical antibiotic coverage, including liposomal amphotericin B, was started. Blood cultures showed growth of Candida albicans, but the central venous catheter tip was negative. Methaemoglobin levels halved in two days (7%), but remained constant during the following two weeks of antifungal treatment. Blood cultures at that point showed growth of S cerevisiae, which is susceptible to amphotericin B, in the absence of any clinical finding; again, the catheter tip was sterile. Methaemoglobin concentration was still abnormal (6.2%). Liposomal amphotericin B treatment was prolonged for a further six days and then discontinued. At this time, methaemoglobin levels were near normal (3%), and blood cultures were negative. The gastrointestinal symptoms resolved with age and full gastrointestinal function was achieved.

Recovery of Saccharomyces two weeks after administration had been stopped suggests persistence in the gut. It is tempting to think that the methaemoglobinemia was caused by the continued presence of the yeasts, perhaps through excessive host production of nitric oxide. Several studies have shown that nitric oxide plays a pivotal role in the interaction between yeasts and the phagocytic system, and it is well known that this radical readily oxidises haemoglobin. It is also reasonable to link late bloodstream invasion by Saccharomyces to previous enteric mucosal damage caused by a Candida infection, which was itself probably gut related. The recovery of S cerevisiae in place of S boulardii has been reported by others, and can be explained by the similarities between the two. It is ironic that the intervention used to prevent sepsis from enteric overgrowth not only did not succeed but was itself a cause of the problem that it was intended to prevent.

M S Lungarotti, D Mezzetti, M Radiconi

Policlínica Manteluce, Via Brunamonti, Perugia, PG 06100, Italy; dm2@unipg.it

References

We were interested to see the article “Oxygen administration in infants,” and letter responses. The original article and letters were unsure of the efficacy of “non-contact” oxygen delivery or “wafting” as it is more commonly known. Our study “The efficacy of noncontact oxygen delivery methods,” demonstrated how effective wafting oxygen can be. We found that an area of 34cm by 37cm obtained a concentration of >30% when oxygen is delivered by face mask at 10 l / minute. Although this is not a substitution for the more reliable methods of administration as detailed by Drs Frey and Shann, in the short term it can be used with confidence.

We caution against holding a self inflating resuscitation bag over an infant’s airway (without manipulation of the bag itself), as it delivers a negligible amount of oxygen. It is much more efficient to use the oxygen tubing without any attachments.

P Davies, NETS, Sydney, Australia; daviespatrick@hotmail.com
D Cheng, Department of Oncology, Great Ormond Street Hospital, London, UK
A Fox, Department of Paediatric Allergy, St Mary’s Hospital, London, UK
L Lee, Neonatal Intensive Care Unit, Rosie Maternity Hospital, Cambridge, UK

References

We wish to apologise for an error that occurred in a letter by Daniels et al (Arch Dis Child Fetal Neonatal Ed 2003;88:F257). The first line of the third paragraph should have read: The salient results were that two thirds of granulomas resolved over a three week period without cauterisation.
Neonatologists are not always directly involved in the intensive care of neonates as surgical patients. In my own case this has led to a slightly blinkered approach. I am very familiar with perinatal stabilisation of problems such as chylothorax, subarachnoid stenosis, or necrotising enterocolitis and describe the authors’ perspective on management. There are numerous photographs, radiographs, and drawings in nice balance with the text. Fascinating drawings, intended to complement the “comprehensive description of operative techniques” left me wondering that such complicated operations could be performed without consideration for the patients. The authors are drawn from all over the world, but the book’s style remains uniformly European.

The book begins with a series of chapters dedicated to general and theoretical aspects of the care of these high risk infants. These areas of overlap with standard neonatal texts are very variable and, from my perspective, also very interesting. Some could have been more up to date. It was also interesting for example to see a chapter on neonatal transport written by two paediatric surgeons rather than by neonatologists. Some overlap is inevitable in a book like this. However, I would have preferred, for example that there was more embryology in each surgical chapter or a more comprehensive introductory chapter. A well written chapter on ethics, from a purely North American perspective, occupies eight pages, which is also the space given to parenteral nutrition. The five sides dedicated to respiratory management of the newborn emphasised to me the potential rewards to be reaped from closer integration of training and practice in neonatology and newborn surgery.

The chapters on surgical problems are the book’s strongest area. We have found the book valuable in furthering our understanding of the problems we see on a day to day basis. Many of the lesions in question are very variable and, from my perspective, sure, it is genuinely more readable than a textbook on the subject. A paper on the relation between micronutrients in pregnancy and early infancy and mental and psychomotor development, in which special micronutrient concerns in premature infants were of particular interest to my personal practice.

Discussions after the papers were presented have included and often highlight areas of uncertainty or real practical importance. Of course, in a book such as this there are going to be areas that don’t get covered, and, if you were looking for a comprehensive tome on this subject, then spending your money on a textbook might be better. But many of us purchase textbooks and then allow them to sit on the shelves collecting dust while we only “dip into” them occasionally. The good thing about this type of book is that you might actually end up reading some of it!

N Embleton
Consultant in Neonatal Medicine, Royal Victoria Infirmary, Newcastle upon Tyne, UK; n.d.embleton@ncl.ac.uk
to be contaminated both clinically and in a negative repeated culture. In one infant, blood culture was positive for *Staphylococcus aureus*, and *Enterococcus* grew from culture of the urine in the other. Most admissions (83%) were between June and early October, which are the warmest months of the year in this area. In this low risk group of infants, only two patients had serious bacterial infection. Comparable with the findings of Maayan-Metzger et al., the results of our study dehydrate as the main cause of fever during the first week of life. As most of our cases occurred during summer and early autumn, environmental temperature may have an additive effect in this population.

Use of abbreviations in daily progress notes

Errors in medication and documentation are reported.1,2 These errors, no matter how minor, could have grave consequences for the patient, especially in the paediatric population. The patients at risk were identified by reviewing notes of seven different doctors during the first week of life. As most of our cases were the Roberta’s potential threat to small newborns. Recently, Carroll et al. described problems in residents’ progress notes in a neonatal intensive care unit. Being the busiest centre in the country, managing the care of a large number of seriously sick neonates, are at a very high risk of these errors. In view of this and as a screening audit, we looked at a few progress notes written on our inpatient neonates. One example of a progress note, written by a junior doctor, stated “Prem 32 WOG, F & G: Problems: RDS, IVH II, S/P SVT, Stable on RA, TPR normal, PU, BO, Chest, CVS & abdomen: NAD”. This excessive and inappropriate use of abbreviations is alarming and disturbing. The abbreviations used denoted the following (in order of citation): weeks of gestation, feeder and growth, respiratory distress syndrome, intraventricular grade 2 haemorrhage, status post supraventricular tachycardia, room air, temperature pulse respiration, passed urine, bowel open, cardiovascular system, and no abnormality detected. This prompted us to look further into the inappropriate use of abbreviations in the daily progress notes in our neonatal unit.

A cross section survey was carried out at the Special Care Baby Unit (SCBU), Royal Hospital, Muscat, on 7 October 2003. Thirty consecutive notes were reviewed. The progress notes written by seven different doctors (three registrars and four resident medical officers) were analysed for use of abbreviations. The commonly used ones were: CP (cystic fibrosis), RR (respiratory rate), HR (heart rate), BP (blood pressure), PA (per abdomen), O/E (on examination), NGT (nasogastric tube), UEI (urea and electrolyte i), BGA (blood gas analysis), BBA (born before arrival), TPN (total parental nutrition), SLS (standard liquid solution), STS (standard TPN solution), D/w (discussed with), SBR (serum bilirubin), CTG (cardio- tograph), IUGR (intraterine growth restriction), IVF (in vitro fertilisation), POD (postoperative day), ASD (atrial septum defect), VSD (ventricular septum defect), PDA (patent ductus arteriosus), TR (tricuspid regurgitation), L-R shunt (left to right shunt), TOF (tetrology of Fallot), CRT (capillary refill time). One interesting note that needs separate mention was “Plan is to start ABs after ARC” (ABs, antibiotics; ABC, aerobic blood culture).

We noted a high frequency of the use of abbreviations in our neonatal unit. This was a single day observation; we would expect much more variation in a normal study. Fortunately, none of the abbreviations had resulted in erroneous interpretation, as most of the staff were used to them. However, this does not indicate that it is all right to use abbreviations. Standard abbreviations, such as VSD (ventricular septal defect) and PDA (patent ductus arteriosus), are acceptable, whereas others are not.

Documentation errors have been reported to be an increasing problem in day to day care of patients.3,4 A recent report described the same negligence in documentation by residents. Carroll et al. found discrepancies in the daily progress notes written by a resident doctor in the neonatal intensive care unit. They also found that notes often contained inaccurate information and lacked pertinent information. We looked further into the situation and found extensive use of abbreviations in progress notes.

Our observation is not unique and requires rectification. The solution could be to standardise or eliminate the use of abbreviations in the unit. Total elimination would be difficult, as many of the abbreviations are acceptable. Thus, the use of unacceptable abbreviations should be discouraged. New medical officers should be given brief instruction on the writing of appropriate progress notes. An alternative is to use the electronic information system for all medical transcription and promote progress notes, as described elsewhere.5,6

In conclusion, care of neonates requires good documentation of day to day progress. There use of unacceptable abbreviations should be discouraged. A follow up audit is warranted to look further into the effect and success of our recommendations.

References


Use of nasal continuous positive airway pressure during neonatal transfer

Within neonatal intensive care units, nasal continuous positive airway pressure (nCPAP)
What is the normal range of blood glucose concentration in healthy term newborns?

The report by Dr Nicholl on ‘normal blood glucose concentrations in healthy term newborns’ raises the interesting and important question of how normoglycaemia in newborns can be defined. In a comprehensive review of the literature in 1997, an expert panel of the World Health Organization concluded that there are numerous approaches to defining normoglycaemia, including the statistical approach (which was taken by Dr Nicholl), the metabolic approach (what is the concentration of blood glucose at which normal cell homocostasis is maintained?), the neurophysiological approach (below what concentration of blood glucose does impairment of neurological functions occur?), and perhaps most importantly, the neurodevelopmental approach (does a relation exist between neonatal blood glucose concentrations and the neurodevelopmental outcome of children years later?). These different approaches towards definition of normoglycaemia contribute to the controversy that surrounds this issue. Other factors that influence newborn blood glucose concentrations, even in healthy term newborns, are perinatal complications, mode of delivery, and feeding behaviour. It appears therefore that there is very little solid evidence on which judgment of neonatal blood glucose concentrations can be based. Follow up studies looking at neurodevelopmental outcome of neonatal ‘hypoglycaemia’ (and its treatment) in healthy term infants of various delivery modes and birth weights are urgently needed.

References
1 Nicholl OR. What is the normal range of blood glucose concentrations in healthy term newborns? Arch Dis Child 2003;88:238–9.

Gastric perforation and transillumination

We read with interest the article of Farrugia and colleagues’ about neonatal gastrointestinal perforation. However, there was no mention of:

- Isolated gastric perforation as a cause of neonatal gut perforation, or
- Transillumination as a simple diagnostic tool of pneumoperitoneum.

We highlight these two points relating to a recent case. A 29 week gestation baby girl was born by vaginal delivery. She initially required conventional ventilation for her lung disease. An umbilical arterial catheter was inserted but removed after a few hours due to skin/tissue perforation. On day 2 she was extubated and nCPAP was tried. After a few hours, her condition deteriorated and she returned to conventional ventilation. On day 4, she was started on enteral feeding, using small volumes of breast milk, but had mild abdominal distension and some aspirates. Feeding was stopped. Her abdomen deteriorated and she had persistent metabolic acidosis. Transillumination of her abdomen was positive (fig 1) for pneumoperitoneum and was confirmed by abdominal x ray examination (fig 2).

Gastric perforation is unusual but serious. Various causative factors, including prematurity and nCPAP, have been suggested. Both of these were present in our case. It is also possible that emboli from the umbilical catheter led to small areas of infarction of the stomach wall.

Transillumination is a quick and easy technique for diagnosing pneumoperitoneum, and obviates the need for frequent radiographs.

References

www.archdischild.com

Figure 1 Transillumination of the abdomen showing pneumoperitoneum.

Figure 2 Abdominal radiograph confirming pneumoperitoneum.
Renal fungal ball

Preterm infants are prone to fungal infections because of immaturity of their host defence systems (immunology and skin). Other risk factors include multiple antibiotic therapy, prolonged use of umbilical or percutaneous catheters, total parenteral nutrition, colonisation and/or past mucocutaneous candidiasis, low birth weight, endotracheal tube placement, and congenital malformation.

Common sites for invasive candidiasis are the renal system, eyes, brain, and heart. Diagnostic tests should include blood and urine cultures, renal ultrasound, ophthalmological assessment, cardiac ultrasound, and examination of cerebrospinal fluid.

Candiduria may indicate colonisation, but the presence of other clinical signs increases the risk of invasive candidiasis. Fungal ball is the commonest presentation of renal fungal disease. Clinical presentation may vary and can be obstructive, or non-obstructive, with renal failure.

A baby born at 28 weeks gestation was known to be colonised with *Candida* spp in the first weeks of life. The mother had declined routine antenatal care. The baby was ventilator dependent, with umbilical lines and received multiple broad spectrum antibiotics for possible bacterial sepsis.

After one month the baby developed thrombocytopenia and renal impairment. A renal ultrasound confirmed the presence of a solitary kidney with an echogenic mass. Limited postmortem examination revealed multiple abscesses in the renal parenchyma, which grew *Candida albicans* only.

Invasive fungal infections in very low birthweight babies are currently the subject of a BPSU study (http://bpsu.inopsu.com/current.htm#Invasive).

M Wimalendra

A Reece

R M Nicholl

Neonatal Unit, Northwick Park Hospital, North West London Hospitals NHS Trust, Harrow HA1 3UJ, UK; Richard.nicholl@nwlh.nhs.uk

REFERENCE